About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:4821394
Allelic
Composition
Egr1tm1Jmi/Egr1tm1Jmi
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Egr1tm1Jmi mutation (1 available); any Egr1 mutation (19 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• 15-20 fold increase in spleen weight
• expanded erythroid and myeloid cells in spleen

endocrine/exocrine glands
• ENU treatment at 4 and 20 weeks weeks results in T-cell lymphomas in 53% of mice compared to 26% of controls treated at 3 weeks and 10% of controls treated at 20 weeks
• mice with lymphomas do not develop myeloproliferative disease

liver/biliary system
N
• ethanol feeding does not induce liver steatosis
• slightly elevated liver triglycerides with ethanol feeding
• liver weight/body weight ratio does not increase with ethanol feeding as happens with controls
• hepatocellular proliferation after partial hepatectomy normal for first 36 hours
• proliferation is significantly reduced at 48 hours

cellular
• mitosis impaired between metaphase and anaphase
• lower frequency of mitosis in the liver 48 hours after hepatectomy
• frequency of mitosis in the liver remains more or less constant from 48 to 72 hours after hepatectomy

neoplasm
N
• spontaneous tumors do not develop
• ENU treatment at 4 and 20 weeks weeks results in T-cell lymphomas in 53% of mice compared to 26% of controls treated at 3 weeks and 10% of controls treated at 20 weeks
• mice with lymphomas do not develop myeloproliferative disease
• ENU treatment at 4 and 20 weeks weeks results in T-cell lymphomas in 53% of mice compared to 26% of controls treated at 3 weeks and 10% of controls treated at 20 weeks
• skin tumors induced by treatment with DMBA and TPA appear to be papillomas
• mice treated with the mutagen DMBA and tumor promoter TPA develop skin tumors around 8 weeks rather than 12.5 weeks as in controls

homeostasis/metabolism
• serum alanine aminotransferase is not increased by ethanol feeding whereas levels increase 2 fold in controls
• slightly elevated liver triglycerides with ethanol feeding
• TNF alpha levels remain constant with ethanol feeding whereas they increase 20 fold in controls
• liver weight/body weight ratio does not increase with ethanol feeding as happens with controls
• serum alanine aminotransferase is not increased by ethanol feeding whereas levels increase 2 fold in controls
• TNF alpha levels remain constant with ethanol feeding whereas they increase 20 fold in controls
• no effect of ethanol diet on LPS sensitivity
• ENU treatment at 4 and 20 weeks weeks results in T-cell lymphomas in 53% of mice compared to 26% of controls treated at 3 weeks and 10% of controls treated at 20 weeks
• infarcts are much smaller in total area after temporary middle cerebral artery occlusion
• neurological deficits are mild
• less edema than in controls
• reduced rate of wound healing
• less collagen deposition
• fewer alpha smooth muscle cell positive myofibroblasts

hematopoietic system
• 15-20 fold increase in spleen weight
• expanded erythroid and myeloid cells in spleen
• ineffective erythropoiesis in bone marrow and spleen
• two fold increase in hematopoietic stem cells in the S/G2-M phase of the cell cycle
• no buildup of stem cells in the bone marrow
• level of circulating hematopoietic stem cells is dramatically increased
• dysplastic neutrophils in bone marrow and spleen
• mildly elevated
• elevated numbers of activated microglial cells an macrophage but fewer than in controls

immune system
N
• no effect of ethanol diet on LPS sensitivity
• 15-20 fold increase in spleen weight
• expanded erythroid and myeloid cells in spleen
• dysplastic neutrophils in bone marrow and spleen
• mildly elevated
• elevated numbers of activated microglial cells an macrophage but fewer than in controls
• TNF alpha levels remain constant with ethanol feeding whereas they increase 20 fold in controls
• lower inflammatory response to four daily subcutaneous bleomycin injections
• lower inflammatory response to a single subcutaneous TGF beta injection

respiratory system
N
• bleomycin induced lung pathologies are attenuated
• number and size of subpleural and interstitial fibrotic foci is reduced
• diminished collagen accumulation

vision/eye
• smaller radius of curvature at 40 days of age than in controls
• deeper anterior chamber of the eye at 56 days of age
• longer eyes (axial eye length) than controls at 42 days of age
• reduced refraction relative to controls

nervous system
• elevated numbers of activated microglial cells an macrophage but fewer than in controls
• infarcts are much smaller in total area after temporary middle cerebral artery occlusion
• neurological deficits are mild
• less edema than in controls

integument
• bleomycin induced dermal thickening more modest than in controls
• less sclerotic than controls
• less collagen accumulation
• reduced accumulation of alpha-smooth musclew actin myofibroblasts
• skin tumors induced by treatment with DMBA and TPA appear to be papillomas

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
myelodysplastic syndrome DOID:0050908 OMIM:614286
J:123870


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
04/16/2024
MGI 6.23
The Jackson Laboratory